Business context and reporting period
bioAffinity Technologies, Inc. reported on October 6, 2026, that sales of its CyPathLung test increased through the third quarter of 2026. The company describes the test as a noninvasive tool for assessing lung-cancer likelihood in high-risk individuals.
Key financial and operating information
- CyPath Lung sales increased more than 100% through Q3 2026 compared with the same period in 2025.
- The filing provides no sales dollars, test volumes, margins, profit, cash flow, debt, or liquidity figures.
Material changes and outlook
The company attributes the sales growth to continued clinical adoption. No formal guidance, quantified outlook, or additional management commentary is provided in the supplied filing text.
Important facts to verify
- Review Exhibit 99.1, the referenced press release, for the underlying sales figures and comparison methodology.
- Verify whether the reported growth reflects test volume, revenue, or another sales measure.
- Assess whether adoption and sales growth are translating into improved financial results; this filing does not provide those results.